← brief for 2026-08-31 · Slowing decline

Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.

Article B Peer reviewed Small trial

Key takeaways

Using health records from over 12,000 dialysis patients with diabetes and heart failure, researchers compared those who started GLP-1 drugs to those who started DPP-4 inhibitors. Over two years, the GLP-1 group had about a 20% lower risk of major heart events or death. This was not a randomized trial, but the large size and careful methods make the finding fairly reliable.

Who did this work

Liu PY · Shih CK · Hsieh MH · Lin CC · Liu CY · Lai EC · Li CY · Yu CH · Sung JM

Source

Article · PubMed, the drug frontier · 2026 Jul 30
https://pubmed.ncbi.nlm.nih.gov/42669711/